WM-A1-3389 / Y-Biologics, WMBIO - LARVOL DELTA

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Wellmarker Bio | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • IGSF1 • PD-L1

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (KEYNOTE-E90) (clinicaltrials.gov) - P1 | N=54 | Not yet recruiting | Sponsor: Wellmarker Bio | Trial completion date: Sep 2025 ➔ Feb 2026 | Initiation date: Aug 2023 ➔ Jan 2024 | Trial primary completion date: Sep 2025 ➔ Feb 2026

Combination therapy • Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • PD-L1

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=54 | Not yet recruiting | Sponsor: Wellmarker Bio

Combination therapy • Metastases • New P1 trial • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • PD-L1

Wellmarker Bio Announces Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA (pembrolizumab) (PRNewswire) - "Wellmarker Bio Co., Ltd...announced the company has entered a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) on 7th Feb. Under the agreement, WMBIO will sponsor the Phase 1 (or Phase 1b) clinical trial for WM-A1-3389, a novel therapeutic antibody for Non-Small Cell Lung Cancer (NSCLC) patients with low or no PD-L1 expression, in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy....WMBIO is also planning to expand the target patient group to other solid tumor indications."

Licensing / partnership • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor